Richards, Erica M.
Zanotti-Fregonara, Paolo
Fujita, Masahiro
Newman, Laura
Farmer, Cristan
Ballard, Elizabeth D.
Machado-Vieira, Rodrigo
Yuan, Peixiong
Niciu, Mark J.
Lyoo, Chul Hyoung
Henter, Ioline D.
Salvadore, Giacomo
Drevets, Wayne C.
Kolb, Hartmuth
Innis, Robert B.
Zarate Jr, Carlos A.
Funding for this research was provided by:
National Institute of Mental Health (NCT01851356)
Janssen Pharmaceuticals
Article History
Received: 5 March 2018
Accepted: 30 May 2018
First Online: 3 July 2018
Ethics approval and consent to participate
: This study was approved by the Combined Neuroscience Institutional Review Board of the National Institutes of Health. All participants gave written informed consent before entry into the study.
: Drs. Salvadore, Drevets, and Kolb are full-time employees and shareholders of Janssen Pharmaceuticals, Inc. Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.